» Articles » PMID: 32270167

Coordination Chemistry of [Y(pypa)] and Comparison Immuno-PET Imaging of [Sc]Sc- and [Y]Y-pypa-phenyl-TRC105

Overview
Journal Dalton Trans
Specialty Chemistry
Date 2020 Apr 10
PMID 32270167
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Both scandium-44 and yttrium-86 are popular PET isotopes with appropriate half-lives for immuno-positron emission tomography (immuno-PET) imaging. Herein, a new bifunctional Hpypa ligand, Hpypa-phenyl-NCS, is synthesized, conjugated to a monoclonal antibody, TRC105, and labeled with both radionuclides to investigate the long-term in vivo stability of each complex. While the Sc-labeled radiotracer exhibited promising pharmacokinetics and stability in 4T1-xenograft mice (n = 3) even upon prolonged interactions with blood serum proteins, the progressive bone uptake of the Y-counterpart indicated in vivo demetallation, obviating Hpypa as a suitable chelator for Y ion in vivo. The solution chemistry of [Y(pypa)] was studied in detail and the complex found to be thermodynamically stable in solution with a pM value 22.0, ≥3 units higher than those of the analogous DOTA- and CHX-A''-DTPA-complexes; the Y-result in vivo was therefore most unexpected. To explore further this in vivo lability, Density Functional Theory (DFT) calculation was performed to predict the geometry of [Y(pypa)] and the results were compared with those for the analogous Sc- and Lu-complexes; all three adopted the same coordination geometry (i.e. distorted capped square antiprism), but the metal-ligand bonds were much longer in [Y(pypa)] than in [Lu(pypa)] and [Sc(pypa)], which could indicate that the size of the binding cavity is too small for the Y ion, but suitable for both the Lu and Sc ions. Considered along with results from [Y][Y(pypa-phenyl-TRC105)], it is noted that when matching chelators with radionuclides, chemical data such as the thermodynamic stability and in vitro inertness, albeit useful and necessary, do not always translate to in vivo inertness, especially with the prolonged blood circulation of the radiotracer bound to a monoclonal antibody. Although Hpypa is a nonadentate chelator, which theoretically matches the coordination number of the Y ion, we show herein that its binding cavity, in fact, favors smaller metal ions such as Sc and Lu and further exploitation of the Sc-pypa combination is desired.

Citing Articles

Construction of the Bioconjugate Py-Macrodipa-PSMA and Its In Vivo Investigations with Large La and Small Sc Radiometal Ions.

Hu A, Martin K, Smilowicz D, Aluicio-Sarduy E, Cingoranelli S, Lapi S Eur J Inorg Chem. 2024; 26(35).

PMID: 38495596 PMC: 10939043. DOI: 10.1002/ejic.202300457.


Mo(vi) complexes of amide-imine conjugates for tuning the selectivity of fluorescence recognition of Y(iii) Pb(ii).

Chatterjee S, Ta S, Khanra S, Das D RSC Adv. 2022; 12(51):33293-33303.

PMID: 36425161 PMC: 9677438. DOI: 10.1039/d2ra06035c.


Affinity probes based on small-molecule inhibitors for tumor imaging.

Yi X, Wang Z, Hu X, Yu A Front Oncol. 2022; 12:1028493.

PMID: 36387103 PMC: 9647038. DOI: 10.3389/fonc.2022.1028493.


Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine.

Rigby A, Firth G, Rivas C, Pham T, Kim J, Phanopoulos A Bioconjug Chem. 2022; 33(7):1422-1436.

PMID: 35801668 PMC: 9305974. DOI: 10.1021/acs.bioconjchem.2c00284.

References
1.
Le Fur M, Beyler M, Molnar E, Fougere O, Esteban-Gomez D, Tircso G . The role of the capping bond effect on pyclen Y/Y chelates: full control of the regiospecific N-functionalization makes the difference. Chem Commun (Camb). 2017; 53(69):9534-9537. DOI: 10.1039/c7cc05088g. View

2.
Banerjee S, Foss C, Pullambhatla M, Wang Y, Srinivasan S, Hobbs R . Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. J Nucl Med. 2015; 56(4):628-34. PMC: 4877701. DOI: 10.2967/jnumed.114.149062. View

3.
Gans P, Sabatini A, Vacca A . Investigation of equilibria in solution. Determination of equilibrium constants with the HYPERQUAD suite of programs. Talanta. 1996; 43(10):1739-53. DOI: 10.1016/0039-9140(96)01958-3. View

4.
van Dongen G, Poot A, Vugts D . PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012; 33(3):607-15. PMC: 3342498. DOI: 10.1007/s13277-012-0316-4. View

5.
Helisch A, Forster G, Reber H, Buchholz H, Arnold R, Goke B . Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31(10):1386-92. DOI: 10.1007/s00259-004-1561-6. View